BPIQ Blog

Mar 14, 20191 min read

UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success

Based on robust Ph2B and Ph3 (Japan) data in prior trials with similar design, it appears highly likely that UROV's Vibegron will meet...

Jump start your biotech due diligence

Our platform helps you uncover your next biotech investment opportunity

bottom of page